1. Home
  2. RVYL vs NLSP Comparison

RVYL vs NLSP Comparison

Compare RVYL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVYL
  • NLSP
  • Stock Information
  • Founded
  • RVYL 2007
  • NLSP 2015
  • Country
  • RVYL United States
  • NLSP Switzerland
  • Employees
  • RVYL N/A
  • NLSP N/A
  • Industry
  • RVYL Professional Services
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • RVYL Consumer Discretionary
  • NLSP Health Care
  • Exchange
  • RVYL Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • RVYL 5.4M
  • NLSP 12.4M
  • IPO Year
  • RVYL N/A
  • NLSP 2021
  • Fundamental
  • Price
  • RVYL $0.64
  • NLSP $2.50
  • Analyst Decision
  • RVYL Hold
  • NLSP
  • Analyst Count
  • RVYL 1
  • NLSP 0
  • Target Price
  • RVYL N/A
  • NLSP N/A
  • AVG Volume (30 Days)
  • RVYL 24.4M
  • NLSP 411.8K
  • Earning Date
  • RVYL 08-12-2025
  • NLSP 07-15-2025
  • Dividend Yield
  • RVYL N/A
  • NLSP N/A
  • EPS Growth
  • RVYL N/A
  • NLSP N/A
  • EPS
  • RVYL N/A
  • NLSP N/A
  • Revenue
  • RVYL $54,357,000.00
  • NLSP N/A
  • Revenue This Year
  • RVYL $27.50
  • NLSP N/A
  • Revenue Next Year
  • RVYL $35.71
  • NLSP N/A
  • P/E Ratio
  • RVYL N/A
  • NLSP N/A
  • Revenue Growth
  • RVYL N/A
  • NLSP N/A
  • 52 Week Low
  • RVYL $0.36
  • NLSP $1.30
  • 52 Week High
  • RVYL $2.40
  • NLSP $15.59
  • Technical
  • Relative Strength Index (RSI)
  • RVYL 43.75
  • NLSP 52.64
  • Support Level
  • RVYL $0.76
  • NLSP $2.16
  • Resistance Level
  • RVYL $0.98
  • NLSP $3.08
  • Average True Range (ATR)
  • RVYL 0.10
  • NLSP 0.24
  • MACD
  • RVYL 0.00
  • NLSP -0.00
  • Stochastic Oscillator
  • RVYL 2.94
  • NLSP 30.21

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: